Wave Life Sciences shares, which skyrocketed Monday on favorable interim Phase 1 data for weight loss drug WVE-007, gained on Tuesday after analysts raised price targets. Shares rose 147% to $18.52 on ...

Interim data from Wave Life Sciences' INLIGHT trial showed promising results for WVE-007, an investigational treatment for obesity.

Wave Life Sciences reports promising phase 1 results for obesity therapy WVE-007, showing fat loss and increased lean mass.

Wave Life Sciences shares jumped in premarket trading Monday after it said it received encouraging preliminary trial data for its investigational weight loss drug WVE-007. Shares advanced nearly 78% ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...

Wolfe Research upgraded life sciences toolmaker Waters Corporation (WAT) to Outperform from Peer Perform on Wednesday, citing ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

The world's first GLP-1 weight-loss treatment for pets has begun with successful cat dosing. The six-month implant could ...

Buying life insurance can also an important strategy for seniors. A policy can help you replace a plan that ended when you left your job, cover funeral expenses or leave a financial legacy for your ...

Science writer David Berreby shares his personal journey with griefbots and discusses how they can offer unexpected comfort, insight and connection in the wake of loss. Kendra Pierre-Louis steps in as ...

We are at a critical time and supporting climate journalism is more important than ever. Science News and our parent organization, the Society for Science, need your help to strengthen environmental ...